Text Size

Long-term Follow-up in Patients Affected With Acrofacial Vitiligo

This study is currently recruiting participants.
Verified October 2011 by Irmandade da Santa Casa de Misericordia de Curitiba
Sponsor:
Information provided by (Responsible Party):
Caio Cesar Silva de Castro, Irmandade da Santa Casa de Misericordia de Curitiba
ClinicalTrials.gov Identifier:
NCT01459055
First received: October 21, 2011
Last updated: February 28, 2012
Last verified: October 2011
History of Changes
  Purpose

Acrofacial vitiligo is a clinical form of vitiligo characterized by macules in distal digits, periorificial-facial and ano-genital areas. Vitiligo European Task Force classifies vitiligo as generalized or localized; generalized vitiligo may be further sub-divided into acrofacial, vulgaris and universalis, and localized vitiligo, into segmental and focal. Some authors do not believe that acrofacial is a real vitiligo clinical form, considering it as an initial form of vulgaris vitiligo. The aim of this study is to follow early- diagnosed acrofacial patients during ten years in order to define if these patients will maintain this clinical form or will evolute to a more severe clinical form.


Condition
Vitiligo

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo

Resource links provided by NLM:

MedlinePlus related topics: Vitiligo
U.S. FDA Resources

Further study details as provided by Irmandade da Santa Casa de Misericordia de Curitiba:

Estimated Enrollment: 100
Study Start Date: August 2010
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients of both genders affected by acrofacial vitiligo diagnosed by one single dermatologist.

Criteria

Inclusion Criteria:

  1. Patients of both genders, aged older than years, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol;
  2. Presence of acrofacial vitiligo;
  3. Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines.

Exclusion Criteria:

1- Subjects assessed as not suitable for the study in the opinion of the investigator

2 -Inability to complete survey

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01459055

Contacts
Contact: Caio Cesar C Castro, MD, PhD 00554135682036 caio.castro@pucpr.br

Locations
Brazil
Irmandade da Santa Casa de Misericórdia de Curitiba Recruiting
Curitiba, Parana, Brazil, 80730000
Contact: Caio Cesar Silva de Castro, MD, PhD     00554135682036     caio.castro@pucpr.br    
Principal Investigator: Caio C Silva de Castro, MD, PhD            
Sponsors and Collaborators
Irmandade da Santa Casa de Misericordia de Curitiba
Investigators
Principal Investigator: Caio C Silva de Castro, MD, PhD Irmandade da Santa Casa de Misericórdia de Curitiba
  More Information

No publications provided

Responsible Party: Caio Cesar Silva de Castro, MD, PhD, Irmandade da Santa Casa de Misericordia de Curitiba
ClinicalTrials.gov Identifier: NCT01459055     History of Changes
Other Study ID Numbers: ACRO01
Study First Received: October 21, 2011
Last Updated: February 28, 2012
Health Authority: Brazil: Ethics Committee

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013